Junshi becomes first dual-listed biopharma firm after $692m STAR IPO

Junshi becomes first dual-listed biopharma firm after $692m STAR IPO

Source: Volodymyr Hryshchenko/Unsplash

16 July, 2020

biopharmaceutical Hillhouse Capital Junshi Biosciences STAR Market

Printed by Unregistered user on Mon, 21 Jul 2025 08:44:05 GMT

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

Subscribe to Newsletter

You may also like

Shanghai Junshi Biosciences soars on HK debut after $394m IPO

Hillhouse-backed Genor Biopharma files for $320m HK IPO

Read more from Greater China

China’s humanoid robot maker EngineAI snaps over $139m in fresh funding

Geely-backed NEV brand Farizon’s unit secures $200m in fresh funding